OTCPK:IMRS.Q

Stock Analysis Report

Executive Summary

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • IMRIS's last earnings update was 1630 days ago.
  • IMRIS is not covered by any analysts.

Share Price & News

How has IMRIS's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:IMRS.Q

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

-95.0%

OTCPK:IMRS.Q

9.1%

US Medical Equipment

2.0%

US Market

IMRS.Q underperformed the Medical Equipment industry which returned 8.7% over the past year.

IMRS.Q underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

IMRS.QIndustryMarket
7 Day0%-0.9%1.3%
30 Day0%0.7%3.9%
90 Day0%4.4%3.4%
1 Year-95.0%-95.0%10.0%9.1%4.2%2.0%
3 Year-98.5%-98.5%70.7%65.5%47.2%37.6%
5 Year-100.0%-100.0%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is IMRIS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is IMRIS undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether IMRIS is trading at an attractive price based on the cash flow it is expected to produce in the future. But as IMRIS has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine IMRIS's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through IMRIS regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is IMRIS expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IMRIS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine IMRIS's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access IMRIS's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has IMRIS performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, IMRIS has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is IMRIS's financial position?


In this section we usually analyse IMRIS's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. IMRIS has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of IMRS.Q’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when IMRIS's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is IMRIS's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate IMRIS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate IMRIS's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as IMRIS has not reported any payouts.

Unable to verify if IMRIS's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as IMRIS has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of IMRIS's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Andy Flanagan 0

3.6yrs

Tenure

0

Mr. Andrew M. Flanagan, also known as Andy, has been the Chief Executive Officer and President at IMRIS, Inc. since February 22, 2016. Mr. Flanagan served as Chief Executive Officer of Telcare, Inc. Mr. Fl ...


Management Age and Tenure

2.9yrs

Average Tenure

The tenure for the IMRIS management team is about average.


Board Age and Tenure

6.3yrs

Average Tenure

65yo

Average Age

The tenure for the IMRIS board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Andy Flanagan

    CEO & President

    • Tenure: 3.6yrs
  • Rob Korn (54yo)

    Senior Vice President of Global Sales and Marketing

    • Tenure: 2.5yrs
  • Maurice Holloman

    Executive Vice President of Operations - Customer Support & Customer Engineering

    • Tenure: 3.3yrs
    • Compensation: US$255.29k
  • Peter Simpson

    Senior Vice President of Research & Development

    • Tenure: 1.7yrs

Board Members

  • Steve Armstrong (68yo)

    Director

    • Tenure: 6.1yrs
    • Compensation: US$56.99k
  • Jim Hickey (65yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$56.99k
  • Carey Diamond

    Director

    • Tenure: 13.5yrs
    • Compensation: US$70.58k
  • Blaine Hobson

    Director

    • Tenure: 13.5yrs
    • Compensation: US$55.64k
  • Bill Fraser

    Director

    • Tenure: 12.1yrs
    • Compensation: US$79.63k
  • Vipul Patel

    Member of SYMBIS Advisory Board

    • Tenure: 6yrs
  • Garnette Sutherland

    Member of SYMBIS Advisory Board

    • Tenure: 6.3yrs
  • David Roberts

    Member of SYMBIS Advisory Board

    • Tenure: 6.3yrs
  • Melvin Field

    Member of SYMBIS Advisory Board

    • Tenure: 6.3yrs
  • Greg Sorensen (57yo)

    Executive Chairman

    • Tenure: 3.6yrs

Company Information

IMRIS Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IMRIS Inc.
  • Ticker: IMRS.Q
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$6.259k
  • Shares outstanding: 62.59m
  • Website: https://www.imris.com

Number of Employees


Location

  • IMRIS Inc.
  • 100-1370 Sony Place
  • Winnipeg
  • Manitoba
  • R3T 1N5
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMRS.QOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2007

Biography

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:10
End of Day Share Price2019/09/13 00:00
Earnings2014/12/31
Annual Earnings2014/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.